{"id":"salbutamol-pmdi","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, providing rapid symptomatic relief of bronchoconstriction. It is a short-acting beta-2 agonist (SABA) used primarily for acute relief of asthma and COPD symptoms.","oneSentence":"Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:15.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute relief of bronchospasm in asthma"},{"name":"Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)"},{"name":"Prevention of exercise-induced bronchospasm"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT03900494","phase":"NA","title":"Comparing the Efficacy of Two Valved Holding Chambers in Acute Wheezing","status":"COMPLETED","sponsor":"Tampere University","startDate":"2019-04-17","conditions":"Bronchitis Obstructive, Bronchiolitis; Obstruction, Bronchospasm; Bronchitis","enrollment":80},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT06816342","phase":"PHASE4","title":"Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-11-01","conditions":"Asthmatic Patients, MDI, Aerosol Generating Procedure","enrollment":120},{"nctId":"NCT06482294","phase":"PHASE2","title":"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2024-06-18","conditions":"Asthma","enrollment":80},{"nctId":"NCT06271408","phase":"PHASE1","title":"Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging","status":"UNKNOWN","sponsor":"Polarean, Inc.","startDate":"2024-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":6},{"nctId":"NCT05381415","phase":"","title":"Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2024-06-10","conditions":"COPD, Lung Injury","enrollment":30},{"nctId":"NCT06040424","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-09-28","conditions":"COPD","enrollment":74},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT04606394","phase":"PHASE4","title":"Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD","status":"COMPLETED","sponsor":"Pulmonary Research Institute of Southeast Michigan","startDate":"2020-12-02","conditions":"COPD","enrollment":30},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT04446637","phase":"PHASE3","title":"Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2021-09-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT01511367","phase":"PHASE3","title":"Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2012-03","conditions":"Asthma","enrollment":498},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT01252758","phase":"PHASE2","title":"Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma","status":"WITHDRAWN","sponsor":"Acerus Pharmaceuticals Corporation","startDate":"2012-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT00605891","phase":"PHASE2","title":"Dose Finding Study of CHF 4226 for Treating Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":278},{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT00861926","phase":"PHASE3","title":"Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-03","conditions":"Asthma","enrollment":2079},{"nctId":"NCT01344655","phase":"PHASE4","title":"Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT02542254","phase":"PHASE2","title":"The Effects of RPL554 on Top of Standard COPD Reliever Medications","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2015-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":36},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01096017","phase":"PHASE3","title":"To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":"Asthma","enrollment":24},{"nctId":"NCT00746330","phase":"PHASE2","title":"Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Asthma","enrollment":32},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00640484","phase":"PHASE2","title":"Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00646594","phase":"PHASE3","title":"Atlantis Symbicort","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":1200},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saltanol"],"phase":"phase_3","status":"active","brandName":"Salbutamol pMDI","genericName":"Salbutamol pMDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}